Your browser doesn't support javascript.
loading
TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer.
De Laere, Bram; Oeyen, Steffi; Mayrhofer, Markus; Whitington, Tom; van Dam, Pieter-Jan; Van Oyen, Peter; Ghysel, Christophe; Ampe, Jozef; Ost, Piet; Demey, Wim; Hoekx, Lucien; Schrijvers, Dirk; Brouwers, Barbara; Lybaert, Willem; Everaert, Els G; De Maeseneer, Daan; Strijbos, Michiel; Bols, Alain; Fransis, Karen; Beije, Nick; de Kruijff, Inge E; van Dam, Valerie; Brouwer, Anja; Goossens, Dirk; Heyrman, Lien; Van den Eynden, Gert G; Rutten, Annemie; Del Favero, Jurgen; Rantalainen, Mattias; Rajan, Prabhakar; Sleijfer, Stefan; Ullén, Anders; Yachnin, Jeffrey; Grönberg, Henrik; Van Laere, Steven J; Lindberg, Johan; Dirix, Luc Y.
Afiliação
  • De Laere B; Center for Oncological Research (CORE), University of Antwerp, Antwerp, Belgium. bramdelaere@gmail.com.
  • Oeyen S; Center for Oncological Research (CORE), University of Antwerp, Antwerp, Belgium.
  • Mayrhofer M; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Whitington T; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • van Dam PJ; Center for Oncological Research (CORE), University of Antwerp, Antwerp, Belgium.
  • Van Oyen P; HistoGeneX NV, Wilrijk, Antwerp, Belgium.
  • Ghysel C; Department of Urology, AZ Sint-Jan, Brugge, Belgium.
  • Ampe J; Department of Urology, AZ Sint-Jan, Brugge, Belgium.
  • Ost P; Department of Urology, AZ Sint-Jan, Brugge, Belgium.
  • Demey W; Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium.
  • Hoekx L; Department of Oncology, AZ KLINA, Brasschaat, Belgium.
  • Schrijvers D; Department of Urology, Antwerp University Hospital, Antwerp, Belgium.
  • Brouwers B; Department of Oncology, ZNA Middelheim, Antwerp, Belgium.
  • Lybaert W; Department of Oncology, AZ Sint-Jan, Brugge, Belgium.
  • Everaert EG; Department of Oncology, AZ Nikolaas, Sint-Niklaas, Belgium.
  • De Maeseneer D; Department of Oncology, AZ Nikolaas, Sint-Niklaas, Belgium.
  • Strijbos M; Department of Oncology, AZ Sint-Lucas, Brugge, Belgium.
  • Bols A; Department of Oncology, AZ KLINA, Brasschaat, Belgium.
  • Fransis K; Department of Oncology, AZ Sint-Jan, Brugge, Belgium.
  • Beije N; Department of Urology, Antwerp University Hospital, Antwerp, Belgium.
  • de Kruijff IE; Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • van Dam V; Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Brouwer A; Center for Oncological Research (CORE), University of Antwerp, Antwerp, Belgium.
  • Goossens D; Center for Oncological Research (CORE), University of Antwerp, Antwerp, Belgium.
  • Heyrman L; Agilent Technologies, Niel, Belgium.
  • Van den Eynden GG; Agilent Technologies, Niel, Belgium.
  • Rutten A; Department of Pathology, GZA Hospitals Sint-Augustinus, Antwerp, Belgium.
  • Del Favero J; Department of Oncology, GZA Hospitals Sint-Augustinus, Antwerp, Belgium.
  • Rantalainen M; Agilent Technologies, Niel, Belgium.
  • Rajan P; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Sleijfer S; Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
  • Ullén A; Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Yachnin J; Department of Oncology-Pathology, Karolinska Institutet and University Hospital, Stockholm, Sweden.
  • Grönberg H; Department of Oncology-Pathology, Karolinska Institutet and University Hospital, Stockholm, Sweden.
  • Van Laere SJ; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Lindberg J; Center for Oncological Research (CORE), University of Antwerp, Antwerp, Belgium.
  • Dirix LY; Department of Medical Epidemiology and Biostatistics, Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden.
Clin Cancer Res ; 25(6): 1766-1773, 2019 03 15.
Article em En | MEDLINE | ID: mdl-30209161
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Biomarcadores Tumorais / Proteína Supressora de Tumor p53 / Antagonistas de Receptores de Andrógenos / Neoplasias de Próstata Resistentes à Castração / Antineoplásicos Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Humans / Male Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Bélgica
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Biomarcadores Tumorais / Proteína Supressora de Tumor p53 / Antagonistas de Receptores de Andrógenos / Neoplasias de Próstata Resistentes à Castração / Antineoplásicos Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Humans / Male Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Bélgica